Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
First Claim
Patent Images
1. A pharmaceutical composition comprising as an active ingredient at least one olanzapine polymorph selected from Form III olanzapine, Form IV olanzapine, Form V olanzapine, and salts and mixtures thereof;
- and one or more pharmaceutically acceptable carriers, excipients or diluents;
wherein Forms III, IV and V olanzapine are olanzapine polymorphs having typical x-ray powder diffraction patterns represented by the following interplanar spacings;
FORM-IIIFORM-IVFORM IVd-spacing (Å
)d-spacing (Å
)d-spacing (Å
) 10.31569.948710.59327.17138.507410.21706.50148.21039.95035.51654.81728.52594.85414.71147.10164.55784.61226.07314.49384.52825.20414.45364.23404.98564.25884.09014.81533.98983.75744.75143.72883.69894.53023.56264.47143.02624.22714.13073.98803.77633.71673.5315.
3 Assignments
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions containing Form III, Form IV, Form V olanzapine and/or pharmaceutically acceptable salts thereof. The pharmaceutical compositions are useful for the treatment of psychotic conditions, mild anxiety and gastrointestinal conditions. In particular, the compositions are useful for treating schizophrenia and related disorders, acute mania, Bipolar I Disorder, psychotic mood disorder and psychosis in patients with Alzheimer'"'"'s disease.
-
Citations
19 Claims
-
1. A pharmaceutical composition comprising as an active ingredient at least one olanzapine polymorph selected from Form III olanzapine, Form IV olanzapine, Form V olanzapine, and salts and mixtures thereof;
- and
one or more pharmaceutically acceptable carriers, excipients or diluents;
wherein Forms III, IV and V olanzapine are olanzapine polymorphs having typical x-ray powder diffraction patterns represented by the following interplanar spacings;
FORM-III FORM-IV FORM IV d-spacing (Å
)d-spacing (Å
)d-spacing (Å
)10.3156 9.9487 10.5932 7.1713 8.5074 10.2170 6.5014 8.2103 9.9503 5.5165 4.8172 8.5259 4.8541 4.7114 7.1016 4.5578 4.6122 6.0731 4.4938 4.5282 5.2041 4.4536 4.2340 4.9856 4.2588 4.0901 4.8153 3.9898 3.7574 4.7514 3.7288 3.6989 4.5302 3.5626 4.4714 3.0262 4.2271 4.1307 3.9880 3.7763 3.7167 3.5315. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- and
-
11. A pharmaceutical composition containing as an active ingredient at least one olanzapine polymorph selected from Form III olanzapine, Form IV olanzapine, Form V olanzapine, and salts and mixtures thereof;
-
wherein Forms III, IV and V olanzapine are olanzapine polymorphs having typical x-ray powder diffraction patterns represented by the following interplanar spacings;
FORM-III FORM-IV FORM IV d-spacing (Å
)d-spacing (Å
)d-spacing (Å
)10.3156 9.9487 10.5932 7.1713 8.5074 10.2170 6.5014 8.2103 9.9503 5.5165 4.8172 8.5259 4.8541 4.7114 7.1016 4.5578 4.6122 6.0731 4.4938 4.5282 5.2041 4.4536 4.2340 4.9856 4.2588 4.0901 4.8153 3.9898 3.7574 4.7514 3.7288 3.6989 4.5302 3.5626 4.4714 3.0262 4.2271 4.1307 3.9880 3.7763 3.7167 3.5315. - View Dependent Claims (13, 14, 15, 17, 18, 19)
-
-
12. A method of treating a patient having a psychotic condition, mild anxiety or gastrointestinal condition comprising administering a therapeutically effective amount of at least one olanzapine polymorph to said patient;
-
wherein the at least one olanzapine polymorph is selected from Form III olanzapine, Form IV olanzapine, Form V olanzapine, and salts and mixtures thereof; and
wherein Forms III, IV and V olanzapine are olanzapine polymorphs having typical x-ray powder diffraction patterns represented by the following interplanar spacings;
FORM-III FORM-IV FORM IV d-spacing (Å
)d-spacing (Å
)d-spacing (Å
)10.3156 9.9487 10.5932 7.1713 8.5074 10.2170 6.5014 8.2103 9.9503 5.5165 4.8172 8.5259 4.8541 4.7114 7.1016 4.5578 4.6122 6.0731 4.4938 4.5282 5.2041 4.4536 4.2340 4.9856 4.2588 4.0901 4.8153 3.9898 3.7574 4.7514 3.7288 3.6989 4.5302 3.5626 4.4714 3.0262 4.2271 4.1307 3.9880 3.7763 3.7167 3.5315.
-
-
16. A method of treating a patient having a psychotic condition selected from schizophrenia and related disorders, acute mania, Bipolar I Disorder, psychotic mood disorder and psychosis associated with Alzheimer'"'"'s disease comprising administering a therapeutically effective amount of at least one olanzapine polymorph to said patient;
-
wherein the at least one olanzapine polymorph is selected from Form III olanzapine, Form IV olanzapine, Form V olanzapine, and salts and mixtures thereof; and
wherein Forms III, IV and V olanzapine are olanzapine polymorphs having typical x-ray powder diffraction patterns represented by the following interplanar spacings;
FORM-III FORM-IV FORM IV d-spacing (Å
)d-spacing (Å
)d-spacing (Å
)10.3156 9.9487 10.5932 7.1713 8.5074 10.2170 6.5014 8.2103 9.9503 5.5165 4.8172 8.5259 4.8541 4.7114 7.1016 4.5578 4.6122 6.0731 4.4938 4.5282 5.2041 4.4536 4.2340 4.9856 4.2588 4.0901 4.8153 3.9898 3.7574 4.7514 3.7288 3.6989 4.5302 3.5626 4.4714 3.0262 4.2271 4.1307 3.9880 3.7763 3.7167 3.5315.
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeCipla (EU) Limited (Cipla Limited)
-
Original AssigneeU & I Pharmaceuticals, Ltd.
-
InventorsRao, Dharmaraj R., Kankan, Rajendra N., Hamied, Yusuf K.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/220
-
CPC Class CodesA61K 31/551 having two nitrogen atoms, ...A61P 25/18 Antipsychotics, i.e. neurol...C07D 495/04 Ortho-condensed systems
